On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.

On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.